154 related articles for article (PubMed ID: 21755589)
1. Xmn1-G γ polymorphism and clinical predictors of severity of disease in β-thalassemia intermedia.
Oberoi S; Das R; Panigrahi I; Kaur J; Marwaha RK
Pediatr Blood Cancer; 2011 Dec; 57(6):1025-8. PubMed ID: 21755589
[TBL] [Abstract][Full Text] [Related]
2. The Xmn1 polymorphic site 5' to the (G)gamma gene and its correlation to the (G)gamma:(A)gamma ratio, age at first blood transfusion and clinical features in beta-thalassemia patients from Western Iran.
Nemati H; Rahimi Z; Bahrami G
Mol Biol Rep; 2010 Jan; 37(1):159-64. PubMed ID: 19444645
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major.
Sharma N; Das R; Kaur J; Ahluwalia J; Trehan A; Bansal D; Panigrahi I; Marwaha RK
Eur J Haematol; 2010 Jun; 84(6):531-7. PubMed ID: 20132300
[TBL] [Abstract][Full Text] [Related]
4. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of the spectrum of interactions of CAP+1 (A-->C), a silent beta-globin gene mutation, with other beta-thalassemia mutations and globin gene modifiers in north Indians.
Garewal G; Das R; Awasthi A; Ahluwalia J; Marwaha RK
Eur J Haematol; 2007 Nov; 79(5):417-21. PubMed ID: 17900295
[TBL] [Abstract][Full Text] [Related]
6. Impact of beta globin gene mutations on the clinical phenotype of beta thalassemia in India.
Colah R; Nadkarni A; Gorakshakar A; Phanasgaonkar S; Surve R; Subramaniam PG; Bondge N; Pujari K; Ghosh K; Mohanty D
Blood Cells Mol Dis; 2004; 33(2):153-7. PubMed ID: 15315795
[TBL] [Abstract][Full Text] [Related]
7. The modifying effect of Xmn1-HBG2 on thalassemic phenotype is associated with its linked elements in the beta globin locus control region, including the palindromic site at 5'HS4.
Neishabury M; Zamani S; Azarkeivan A; Abedini SS; Darvish H; Zamani F; Najmabadi H
Blood Cells Mol Dis; 2012 Jan; 48(1):1-5. PubMed ID: 22036762
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of G779A ZHX-2 gene variant with HbF levels in β-thalassemia major.
Munshi A; Dadheech S; Jain S; Joseph J; Al-Hazzani A; Alshatwi AA; Sai Babu M; Rajeshwar K; Jyothy A
Eur J Haematol; 2011 Jun; 86(6):502-6. PubMed ID: 21443521
[TBL] [Abstract][Full Text] [Related]
9. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin E-beta thalassemia: factors affecting phenotype.
Panigrahi I; Agarwal S; Gupta T; Singhal P; Pradhan M
Indian Pediatr; 2005 Apr; 42(4):357-62. PubMed ID: 15876597
[TBL] [Abstract][Full Text] [Related]
11. Association of Xmn1 -158 γG variant with severity and HbF levels in β-thalassemia major and sickle cell anaemia.
Dadheech S; Jain S; Madhulatha D; Sharma V; Joseph J; Jyothy A; Munshi A
Mol Biol Rep; 2014 May; 41(5):3331-7. PubMed ID: 24488321
[TBL] [Abstract][Full Text] [Related]
12. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis and clinical variability of beta-thalassemia syndromes among Indians.
Nadkarni A; Gorakshakar AC; Lu CY; Krishnamoorthy R; Ghosh K; Colah R; Mohanty D
Am J Hematol; 2001 Oct; 68(2):75-80. PubMed ID: 11559945
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of thalassemia intermedia in Iran.
Akbari MT; Izadi P; Izadyar M; Kyriacou K; Kleanthous M
Hemoglobin; 2008; 32(5):462-70. PubMed ID: 18932071
[TBL] [Abstract][Full Text] [Related]
15. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-beta-thalassemia in Northeast Thailand.
Nuntakarn L; Fucharoen S; Fucharoen G; Sanchaisuriya K; Jetsrisuparb A; Wiangnon S
Blood Cells Mol Dis; 2009; 42(1):32-5. PubMed ID: 18951049
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of gamma-globin promoters, HS-111 and 3'HS1, in beta-thalassemia intermedia patients associated with high levels of Hb F.
Hamid M; Mahjoubi F; Akbari MT; Arab A; Zeinali S; Karimipoor M
Hemoglobin; 2009; 33(6):428-38. PubMed ID: 19958188
[TBL] [Abstract][Full Text] [Related]
17. β- and α-Thalassemia intermedia in Basra, Southern Iraq.
Abdulwahid DA; Hassan MK
Hemoglobin; 2013; 37(6):553-63. PubMed ID: 23944608
[TBL] [Abstract][Full Text] [Related]
18. Complications of β-thalassemia intermedia in Iran during 1996-2010 (single-center study).
Rafsanjani KA; Mafi N; Tafreshi RI
Pediatr Hematol Oncol; 2011 Sep; 28(6):497-508. PubMed ID: 21728720
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
20. Molecular understanding of Indian untransfused thalassemia intermedia.
Nadkarni A; Dabke P; Colah R; Ghosh K
Int J Lab Hematol; 2015 Dec; 37(6):791-6. PubMed ID: 26226914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
